Public Notice on the Selection Results of the Sub-Funds of Nanjing Zijin Sci-Tech Innovation Master Fund Partnership (Limited Partnership)
On September 5, 2025, Nanjing Zijin Sci-Tech Innovation Master Fund Partnership (Limited Partnership) (hereinafter referred to as "Nanjing Sci-Tech Innovation Master Fund") held the third meeting of its Sub-Fund Investment Decision-Making Committee, at which the sub-funds to be equity-participated in by Nanjing Sci-Tech Innovation Master Fund were reviewed and approved. Details are as follows:
The fund has a target scale of RMB 300 million, is planned to be registered and based in Nanjing, with a term of 15 years. Focusing on scientific and technological innovation in the fields of new medicine and life health, the fund will support core technology research, as well as the incubation and transformation of scientific research achievements. It will mainly invest in early-stage projects, including all pre-candidate drug phases and preclinical research of pharmaceuticals, as well as concept verification, engineering prototypes, and clinical verification of medical devices.
In accordance with the requirements specified in the Announcement on the Selection of Managers for Proposed Sub-Funds of Nanjing Sci-Tech Innovation Master Fund, after going through processes such as institutional application, preliminary review of materials, due diligence, expert evaluation, and investment decision-making, the proposed sub-fund to be equity-participated in (attached below) is now publicly announced. The public announcement period is 5 working days, from September 10, 2025 to September 16, 2025.
Any entity or individual with objections to the announced results shall submit them in writing during the public announcement period, and list the reasons for the objections and relevant supporting materials. If the objection is submitted in the name of an entity, the official seal of the entity shall be affixed to the objection materials; if submitted in the name of an individual, the individual’s real name, affiliated unit, contact address, and contact information shall be clearly stated, and the individual shall sign the objection materials. To ensure that the handling of objections is objective, fair, impartial, and timely, any anonymous objections or objections submitted beyond the public announcement period will not be accepted.
Contact Person: Ms. Wang
Contact Phone: 025-86596527
Contact Email: selection@njicg.com
Contact Address: 41F, Building 4, Financial City, Jianye District, Nanjing, Jiangsu Province
Attachment: List of Proposed Sub-Funds to Be Equity-Participated in by Nanjing Sci-Tech Innovation Master Fund
Source: Venture Capital Group
Review: Xue Yao
Release: You Yi
